Scarica l'app Stockscreener
99.61
0.79%
-0.79
Dopo l'orario di chiusura:
99.50
-0.11
-0.11%
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Why (INBX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Inhibrx Biosciences stock reports stronger cancer study data - ad-hoc-news.de
Inhibrx Biosciences, Inc. (INBX) stock price, news, quote and history - Yahoo Finance UK
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? - insidermonkey.com
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock By Investing.com - Investing.com Nigeria
Form 4 Inhibrx Biosciences Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 Inhibrx Biosciences Inc For: 23 September - Investing.com India
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock - Investing.com
Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Inhibrx Biosciences stock gains on insider buying and trial progress - ad-hoc-news.de
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
Inhibrx Biosciences stock gains institutional support as Bank of America invests - ad-hoc-news.de
Inhibrx Biosciences Director Kristiina Vuori Receives Corrected Stock Option Grant - Kalkine Media
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing - Kalkine Media
Director at Inhibrx (NASDAQ: INBX) awarded 10,000 options - Stock Titan
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036 - Stock Titan
Inhibrx (INBX) corrects director's 10,000-option grant - Stock Titan
Inhibrx (INBX) corrects 10,000-option grant to director - Stock Titan
Insider Stock Purchases: September 18, 2026 - Moomoo
Inhibrx Biosciences (NASDAQ: INBX) Director Kayyem Jon Faiz Acquires 5,000 Shares at $100 Each - Kalkine Media
Citizens reiterates Market Perform on Inhibrx Biosciences stock By Investing.com - Investing.com Canada
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock By Investing.com - Investing.com Australia
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock - Investing.com
Family trust of Inhibrx (INBX) director adds 5,000 shares at $100 - Stock Titan
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? - The Motley Fool
Director’s trust sells 1,500 Inhibrx (INBX) shares - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
Inhibrx Biosciences gains FDA acceptance for oz... - Pluang
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106 - Seeking Alpha
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - webull.com
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com South Africa
Director trust at Inhibrx (INBX) proposes $55.9K stock sale - Stock Titan
Inhibrx Biosciences Director Kimberly Manhard Sells 1,000 Shares via Revocable Trust in September 2026 - Kalkine Media
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx, Eikon rise after insider buying - TradingView
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - Quiver Quantitative
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates - Benzinga
Inhibrx reports INBRX-106 Phase 2 cancer trial results - grafa.com
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial - Seeking Alpha
Inhibrx Biosciences Announces Primary Endpoint Results from Phase 2 HexAgon Study Of INBRX-106 In Combination With Pembrolizumab In HNSCC - marketscreener.com
Phase 2 primary endpoint results for INBRX106 revealed by Inhibrx Biosciences in HNSCC trial - Traders Union
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study - PR Newswire
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study - AOL.ca
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):